CorMedix
CRMD
38 hedge funds and large institutions have $8.11M invested in CorMedix in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 5 closing their positions.
0.36% less ownership
Funds ownership: 2.97% → 2.61% (-0.36%)
3% less funds holding
Funds holding: 39 → 38 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
44% less capital invested
Capital invested by funds: $14.4M → $8.11M (-$6.29M)
91% less call options, than puts
Call options by funds: $72K | Put options by funds: $813K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ST
Spot Trading
Chicago,
Illinois
|
+$36.1K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$24.9K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$23.5K |
| 4 |
ID
Integral Derivatives
New York
|
+$23.1K |
| 5 |
Franklin Resources
San Mateo,
California
|
+$17.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$258K |
| 2 |
Millennium Management
New York
|
-$182K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$154K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$111K |
| 5 |
Goldman Sachs
New York
|
-$88.5K |
CRMD Hedge Fund Activity: Q4 2016 in Review
38 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q4 2016, worth a combined $8.11M — down 44% from $14.4M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CRMD and 4 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 8 added.
The largest buyer was Spot Trading, adding an estimated $36.1K. The largest seller was Vanguard Group, cutting an estimated $258K.
- 38 institutional investors held CorMedix (CRMD) as of Q4 2016, down from 39 in Q3 2016.
- Funds reported $8.11M of CorMedix stock for Q4 2016, down 44% quarter-over-quarter.
- 4 funds opened new CorMedix positions in Q4 2016 and 5 closed out, a net change of -1 holder.
- The largest CorMedix buyer in Q4 2016 was Spot Trading, an estimated $36.1K added.
- The largest CorMedix seller in Q4 2016 was Vanguard Group, an estimated $258K sold.
Based on aggregated 13F filings for Q4 2016.